Illumina Management Team

Francis deSouza was appointed President & CEO of Illumina in 2016 and is responsible for directing all aspects of company strategy, planning, and operations. He initially joined the company as President in 2013, and led Illumina’s business units and core functions responsible for envisioning, developing and producing the company’s products.

Previously, deSouza served as President of Products and Services at Symantec Corporation, where he was responsible for driving the vision for the company’s market-leading portfolio and served in a variety of executive roles. He joined Symantec through the acquisition of IMlogic, where he was co-founder and CEO.

Prior to joining IMlogic, deSouza was co-founder and CEO of Flash Communications, a provider of corporate instant messaging that was acquired by Microsoft. Following the acquisition, he joined Microsoft and led the team responsible for the development of the company’s enterprise real-time collaboration offerings. Currently, he is a member of the board of directors for The Walt Disney Company.

Francis deSouza received a BS and MS in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology.

Charles Dadswell

Senior Vice President & General Counsel

Charles (Chuck) Dadswell is Senior Vice President and General Counsel of Illumina, where he has worldwide responsibility for all legal and intellectual property matters and is also Illumina's code of ethics compliance officer.

Before joining Illumina, Dadswell was Vice President, General Counsel for North and Latin America and Corporate Director of Global Intellectual Property at bioMerieux. He was previously General Counsel of BioDelivery Sciences International, a specialty pharmaceutical company, and oversaw US intellectual property in a variety of positions with Glaxo, GlaxoWellcome and GlaxoSmithKline.

Dadswell received an LL.M. in patent law and trade regulation from The George Washington University Law School, a J.D. from Thomas M. Cooley Law School and a BS in Pharmacy from Ferris State University.

Paula Dowdy

Senior Vice President & General Manager, Commercial Operations—Europe, Middle East and Africa

Paula Dowdy is the Senior Vice President and General Manager of Commercial Operations for Europe, the Middle East and Africa. Since joining Illumina in August 2016, Dowdy has reorganized the business, identified new markets and returned the region to sustainable growth. In addition, Dowdy played a pivotal role as a senior leader with the launch of the NovaSeq.

Previously, Dowdy was Senior Vice President for Cloud, Software, and Managed Services at Cisco where she drove numerous innovative solutions. During her 20-year tenure at Cisco, she held numerous leadership roles, spearheading product, software and service groups for virtually all customer segments. Having spent the majority of her career in Europe, Dowdy currently resides in London.

Dowdy holds a Master of Business Administration from Pepperdine University and an undergraduate degree from the University of California, Berkeley.

Aimee Hoyt

Senior Vice President & Chief People Officer

Aimee Hoyt is Senior Vice President and Chief People Officer at Illumina, where she is responsible for all aspects of the company’s HR strategies. Hoyt has a successful track record for leading workforce transformation, driving business growth and creating high-impact teams.

Previously, she has held senior positions at some of the world’s best-known technology companies including Hewlett-Packard, Cisco and Sun Microsystems. Most recently, she was the Chief Human Resources Officer at Rackspace, a leading managed cloud computing company, in San Antonio, Texas. She led the HR team and was responsible for helping build, align and develop high-performing global teams. During her tenure, Rackspace was recognized as one of Fortune’s 100 Best Companies to Work For, Top 30 Best Places in Tech and Great Places to Work for Millennials.

Hoyt earned a master’s in human resource development from the Rochester Institute of Technology.

Omead Ostadan

Chief Product and Marketing Officer

Omead Ostadan is Chief Product and Marketing Officer for Illumina. A member of Illumina’s executive management team, Mr. Ostadan is responsible for all aspects of Product Management and Marketing. Mr. Ostadan joined Illumina in 2007 as Vice President of Marketing and built the company’s marketing organization during a period of tremendous growth and diversification. In 2011 Mr. Ostadan assumed the role of Senior Vice President of Product Development and in 2015 his role expanded to include the company’s Global Operations and Quality functions.

Prior to joining Illumina, Mr. Ostadan was Vice President of Marketing at Solexa Inc., where he played a central role in the development of the company’s product and commercial strategy. Prior to joining Solexa Inc. in 2005, Mr. Ostadan held a variety of marketing roles at Applied Biosystems over a nearly 10 year span, including responsibility for managing the company’s high throughput sequencing platforms.

Mr. Ostadan earned his BS in Biochemistry from the University of California at Davis and his MBA from The Wharton School at the University of Pennsylvania.

Li Qing

Vice President and General Manager, Greater China

Li Qing is the Vice President and General Manager of Greater China at Illumina. In his role, Qing is responsible for leading and developing the commercial organization within China, which is a priority growth region for Illumina. Qing oversees all aspects of Illumina’s growth strategy including manufacturing, market development and access, medical and regulatory affairs, regional marketing, competitive positioning, and product launches among others. Qing brings more than 25 years of unparalleled experience in leadership, business management and developing organizations’ capabilities to strengthen market opportunities within the pharmaceutical and life science industries. He has held numerous senior level positions for a number of global companies including GE Healthcare, Baxter,Novartis, and Solvay.

Most recently Qing was General Manager for Life Sciences at GE Healthcare China. He led more than five business units, covering four customer segments across mainland China, Taiwan, and Hong Kong.

Qing received an Executive MBA from the China Europe International Business School.

Bob Ragusa

Senior Vice President, Global Quality & Operations

Bob Ragusa is Senior Vice President of Global Quality & Operations for Illumina where he is responsible for the company’s operations serving clinical and research customers. His organization includes the Manufacturing, Supply Chain, Quality, and Life Cycle Management global teams who are committed to ensure high product quality and customer satisfaction.

Prior to joining Illumina, Ragusa was Executive Vice President of Engineering and Global Operations at Accuray, a radiation oncology company, where he and his team were responsible for the development, manufacturing and distribution of innovative precision treatment solutions. Ragusa served as Senior Vice President of Global Operations for Applied Biosystems from 1997 until 2005.

Ragusa currently serves on Board of Directors for Twist Biosciences. He holds a Bachelor of Science in Electrical Engineering and a Master of Business Administration from the University of Connecticut as well as a Master of Science in Biomedical and Electrical Engineering from Carnegie Mellon University.

Mostafa Ronaghi, PhD

Senior Vice President & Chief Technology Officer

Mostafa Ronaghi, Ph.D., joined Illumina in August 2008. As Senior Vice President and Chief Technology Officer, he is responsible for leading internal research and technology development (RTD) and is co-founder of Illumina Accelerator, the world’s first business accelerator focused solely on creating an innovation ecosystem for the genomics industry.

Ronaghi is an experienced entrepreneur and was involved in founding several start-ups in the life sciences companies. Most recently, he led the formation internally at Illumina of GRAIL Bio, a new company formed to enable cancer screening from a simple blood test. In 2007, Ronaghi co-founded Avantome, a privately held sequencing company (acquired by Illumina in 2008). Before this, he co-founded NextBio, a search engine for life science data (acquired by Illumina in 2013). In 2001, Ronaghi co-founded ParAllele Bioscience, which was eventually acquired by Affymetrix, Inc., and was involved in the development and commercialization of highly multiplexed technology for genetic testing. In 1997, he co-founded Pyrosequencing AB, which was renamed to Biotage in 2003, and led the company to a successful initial public offering in June 2000 on the Stockholm Stock Exchange.

Ronaghi was a principal investigator at Stanford University from 2002 until 2008 and focused on the development of novel tools for molecular diagnostic applications. He serves on the board of directors of BaseHealth and Clear Labs. He is also a member of the Scientific Advisory Board of GRAIL Bio.

Ronaghi earned his Ph.D. from the Royal Institute of Technology in Sweden. He holds more than 30 (pending and issued) patents and has written more than 90 peer-reviewed publications in journals and books.

Sam Samad

Senior Vice President & Chief Financial Officer

Sam Samad joined Illumina in 2017 and holds the role of SVP and Chief Financial Officer with responsibility for the company’s finance, accounting, investor relations, internal audit, treasury, facilities and global information systems functions.

Before joining Illumina, Samad held several senior leadership positions at Cardinal Health including Senior Vice President and Corporate Treasurer, leading all tax and treasury functions. During his tenure as Treasurer, Samad also had operational and financial responsibility for Cardinal Health’s China business. Prior to that, Samad served as Senior Vice President and Chief Financial Officer for Cardinal Health’s $85B pharmaceutical segment, among other leadership roles. Prior to Cardinal Health, Samad spent thirteen years at Eli Lilly and Company, in a variety of sales and finance roles, both domestically and internationally, including his role as Chief Financial Officer of the Canada affiliate prior to leaving Eli Lilly. Samad started his career at Pepsico Inc.

Samad holds a BBA degree from the American University of Beirut in Lebanon and an MBA from McMaster University in Hamilton, Canada.

Samad is currently a member of the Board of Visitors at the Owen Graduate School of Management.

Susan Tousi

Senior Vice President of Product Development

Susan Tousi is Senior Vice President of Product Development at Illumina, where she is responsible for global engineering, consumables, sequencing applications, software and informatics development efforts, ensuring Illumina’s scientists and engineers continue the culture of innovation and product excellence that has been a hallmark of Illumina.

Tousi has more than 25 years of R&D and business leadership at Fortune 100 technology companies and within the life sciences industry. Formerly, Tousi was as a Corporate Vice President and General Manager for Eastman Kodak’s Consumer Inkjet Systems organization. Prior to joining Kodak, Tousi was an R&D program manager for Phogenix Imaging LLC, a joint venture start-up of Hewlett-Packard and Kodak. She previously spent 10 years with Hewlett-Packard in technical and management roles. Tousi played a significant role in the 2017 launch of the NovaSeq Series at Illumina and in 2018 was elected to the National Academy of Engineers for this effort to make genomics accessible and increasing throughput and enabling the path to the $100 human genome.

Tousi holds an MBA degree from UCLA and a BS in Engineering Science and Mechanics from Pennsylvania State University.

Tousi serves as a trustee at the world renowned La Jolla Playhouse.

Mark Van Oene

Senior Vice President & Chief Commercial Officer

Mark Van Oene is Senior Vice President and Chief Commercial Officer for Illumina, a position he has held since 2017. Presently, Van Oene is also the acting General Manager for Greater China. He is responsible for the development and implementation of the company’s commercial strategy and is responsible for world-wide sales, services and marketing. Van Oene was previously Illumina’s Senior Vice President of the Americas region and subsequently named interim Chief Commercial Officer in late 2016. Van Oene joined Illumina in 2006 as Regional Account Manager for Canada. In 2008, he assumed the role of Senior Director of Sales for the Americas and was promoted to Vice President with responsibility for global sales in 2012. In early 2014, Van Oene was named the General Manager for the Americas region, advancing to Senior Vice President in April 2016.

Prior to Illumina, Van Oene was Director, Genotyping Services for Ellipsis Biotherapeutics.

Van Oene earned a BS in biochemistry from Western University and was a Ph.D. candidate at the University of Toronto in Molecular and Medical Genetics.

Gretchen Weightman

Vice President & General Manager—Asia Pacific & Japan

Gretchen Weightman is the Vice President and General Manager of Commercial Operations for Asia Pacific and Japan at Illumina. In her role, Weightman is responsible for leading and developing the commercial organization within the region that includes Japan, Singapore, Australia, South Korea, New Zealand, and India.

Weightman has held several leadership positions within Illumina prior to her current role. She was the Director of Sales for Asia Pacific, where she was responsible for sales of the Asia Pacific region, overseeing five geographical districts for orders, shipments and revenue. Prior to this, Weightman was the Senior Marketing Manager for South Asia Pacific, responsible for the overall marketing strategy and implementation in South East Asia, India, Singapore, Australia, and New Zealand.

Prior to joining Illumina, Weightman worked at Applied Biosystems in a variety of commercial positions including Sales, Marketing, and Product Management. Her professional career started at Genesis Research & Development where she set up the high-throughput sequencing facility.

Weightman graduated from Auckland University with a BSc in Molecular Genetics and a Diploma of Commerce.

Joydeep Goswami, PhD

Senior Vice President of Corporate Development and Strategic Planning

Joydeep Goswami is Senior Vice President of Corporate Development and Strategic Planning where he responsible for driving planning, strategic partnerships and acquisitions.

Most recently, he served as the President of Thermo Fisher Scientific’s Clinical Next-Generation Sequencing (NGS) and Oncology business unit, where he oversaw efforts that drove the adoption of NGS in clinical oncology, research and reproductive health. Goswami has held senior leadership roles across the pharma/biotech, diagnostics and research tool continuum, previously serving at companies such as Life Technologies and Invitrogen, in addition to Thermo Fisher Scientific. He has led teams across various functions, including sales, marketing, R&D and other support functions. Mr. Goswami served as President, Asia Pacific and Japan while at Thermo Fisher Scientific and created the Stem Cells and Regenerative Medicine Business Unit at Invitrogen. Additionally, he spent five years at McKinsey, where he specialized in strategy for pharmaceutical, medical technology and technology companies.

Mr. Goswami holds his MS, PhD in Chemical Engineering, an MBA from MIT and a Bachelor’s degree in Chemical Engineering from the Indian Institute of Technology.

Dr. Phil Febbo

Chief Medical Officer

Dr. Phil Febbo was appointed as Chief Medical Officer in March 2018. In this role, he is responsible for developing and executing the Company’s medical strategy to drive genomic testing into healthcare practice. Dr. Febbo has a successful track record of translational research, clinical excellence, and for embedding molecular insights into clinical care.

Immediately before joining Illumina, Dr. Febbo served as CMO of Genomic Health. Prior to his five years at Genomic Health, Dr. Febbo was a Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology.

Before joining the faculty of UCSF as an associate professor in 2010, Dr. Febbo worked at Duke University Medical Center’s Institute of Genome Sciences and Policy. He completed his internal medicine residency at the Brigham and Women’s Hospital, and his fellowship in oncology at the Dana-Farber Cancer Institute. After which he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). Throughout his career, Dr. Febbo has served as a primary investigator for the Translational Research Program of The Alliance, an NCI-supported cooperative group, where his work focused on incorporating biomarkers into large clinical trials.

Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College and an M.D. from UCSF.